MaxCyte, Inc. (LON:MXCT – Get Free Report)’s share price passed above its fifty day moving average during trading on Thursday . The stock has a fifty day moving average of GBX 0.98 and traded as high as GBX 1.17. MaxCyte shares last traded at GBX 1.14, with a volume of 563,557 shares trading hands.
MaxCyte Stock Performance
The company has a market cap of £1.21 million, a PE ratio of -0.03 and a beta of 1.13. The firm’s fifty day moving average is GBX 0.98 and its 200 day moving average is GBX 1.07. The company has a current ratio of 12.39, a quick ratio of 14.38 and a debt-to-equity ratio of 9.70.
About MaxCyte
MaxCyte is a leading cell-engineering company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and to support innovative, cell-based research. MaxCyte brings best-in-class technology paired with ongoing support designed to facilitate complex engineering of a wide variety of cells and payloads, with the aim of advancing new treatment options for patients. For over 20 years, MaxCyte has been perfecting the art of cell-engineering, venturing beyond today’s process to innovate tomorrow’s solutions.
Featured Articles
- Five stocks we like better than MaxCyte
- Credo Technologies Accelerates AI—Its Stock Price Will Follow
- Qualcomm Goes All-In: The $10B Bet to Crush NVIDIA
- Jabil Just Gave Investors a Stronger Reason to Buy the Dip
- CarMax In Reverse? Why You Should Buy Now Before the Big Catalysts Emerge
Receive News & Ratings for MaxCyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MaxCyte and related companies with MarketBeat.com's FREE daily email newsletter.
